A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: Investigation of enzyme-substrate interactions

Drug Metabolism and Drug Interactions

Volumn 19, Issue 3, 2003, Pages 189-210

  Lewis, David F V ^a   Dickins, Maurice ^b   Lake, Brian G ^c   Goldfarb, Peter S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c BIBRA INTERNATIONAL   (United Kingdom)

Author keywords

CYP2C5 structural template; CYP2D6; Cytochrome P450; Homology modelling; Xenobiotic metabolism and activation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMINO ACID; AMITRIPTYLINE; ASPARTIC ACID; BUFURALOL; CODEINE; CYTOCHROME P450 2C5; CYTOCHROME P450 2D6; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; IMIPRAMINE; METOPROLOL; NORTRIPTYLINE; ONDANSETRON; PROPRANOLOL; QUINIDINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HOMOLOGY MODEL; HYDROGEN BOND; LIPOPHILICITY; MOLECULAR MODEL; MOLECULAR WEIGHT; PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RABBIT; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS;

EID: 0345601902     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2003.19.3.189     Document Type: Article

References (50)

1. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001; 58: 737-747.
2. Nelson, DR. Metazoan cytochrome P450 evolution. Comp Biochem Physiol C 1998; 121: 15-22.
3. Nelson DR. Cytochrome P450 and the individuality of species. Arch Biochem Biophys 1999; 369: 1-10.
4. Lewis DFV. Cytochrome P450: Structure, Function and Mechanism. London: Taylor & Francis, 1996.
5. Lewis DFV. Guide to Cytochromes P450 Structure and Function. London: Taylor & Francis, 2001.
6. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997; 29: 413-580.
7. Evans WE, Relling MV. Pharmacogenetics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
8. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-349.
9. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Laffitte J-J, Meyer UA, Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7: 193-202.
10. Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A. Characterization of cytochrome P4502D6.1 (CYP2D6.1), CYP2D6.2 and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol and debrisoquine. Drug Metab Dispos 2002; 30: 595-601.
11. Lennard MS, Tucker GT, Silas JH, Woods HF. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986; 16: 435-447.
12. Gonzalez FJ. The CYP2D subfamily. In: Ioannides C, ed. Cytochromes P450 Metabolic and Toxicological Aspects, Ch. 8. Boca Raton, FL: CRC Press, 1996; 183-210.
13. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988; 247: 242-247.
14. Wolff T, Dislerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, Guengerich FP. Substrate specificity of human liver cytochrome P450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 1985; 45: 2116-2122.
15. Molden E, Asberg A, Christensen H. Desacetyl-diltiazem displays several fold higher affinity to CYP2D6 compared with CYP3A4. Drug Metab Dispos 2002; 30: 1-3.
16. Onderwater RCA, Venhorst J, Commandeur JNM, Vermeulen NPE. Design, synthesis and characterization of 7-methoxy-4-(aminomethyl)-coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. Chem Res Toxicol 1999; 12: 555-559.
17. Ekins S, de Groot MJ, Jones JP. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 2001; 29: 936-944.
18. de Groot MJ, Ackland MJ, Horne VA, Alex AA, Jones BC. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J Med Chem 1999; 42: 1515-1524.
19. de Groot MJ, Bijloo GJ, van Acker FAA, Fonseca Guerra C, Snijders JG, Vermeulen NPE. Extension of a predictive substrate model for human cytochrome P450 2D6. Xenobiotica 1997; 27: 357-368.
20. de Groot MJ, Vermeulen NPE, Kramer JD, van Acker FAA, Donné-Op den Kelder GM. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102 and P450 108. Chem Res Toxicol 1996; 9: 1079-1091.
21. Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 1997; 27: 319-340.
22. Islam SA, Wolf CR, Lennard MS, Stemberg MJE. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 1991; 12: 2211-2219.
23. Koymans L, Vermeulen NPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, Meuldermans W, Donné-Op den Kelder GM. A predictive model for substrates of cytochrome P450-debrisoquine (IID6). Chem Res Toxicol 1992; 5: 211-219.
24. Koymans LMH, Vermeulen NPE, Baarslag A, Donné-Op den Kelder GM. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J Comp-Aided Mol Design 1993; 7: 281-289.
25. Modi S, Paine MJ, Sutcliffe MJ, Lian L-Y, Primrose WU, Wolf CR, Roberts GCK. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 1996; 35: 4540-4550.
26. Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE. Mammalian cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000; 5: 121-131.
27. Lewis DFV, Modi S, Dickins M. Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. Drug Metab Drug Interact 2001; 18: 221-242.
28. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MMS, Simula AP, Ackland MJ, Sternberg MJE, Lennard MS, Tucker GT, Wolf GR. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 1995; 270: 29055-29058.
29. Smith G, Modi S, Pillai I, Lain L-Y, Sutcliffe MJ, Pritchard MP, Friedberg T, Roberts GCK, Wolf CR. Determinants of the substrate specificity of human cytochrome P450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity. Biochem J 1998; 331: 783-792.
30. Ellis SW, Rowland K, Ackland MJ, Rekka E, Simula AP, Lennard MS, Wolf CR, Tucker GT. Influence of amino acid residue 374 of cytochrome P450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochem J 1996; 316: 647-654.
31. Matsunaga E, Zeugin T, Zanger UM, Aoyama T, Meyer UA, Gonzalez FJ. Sequence requirements for cytochrome P4501ID1 catalytic activity. J Biol Chem 1990; 265: 17197-17201.
32. Hayhurst GP, Harlow J, Chowdry J, Gross E, Hilton E, Lennard MS, Tucker GT, Ellis SW. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. Biochem J 2001; 355: 373-379.
33. Ellis SW. Active site residues of CYP2D6 - fact or fiction? Proc Australian Soc Clin Exp Pharmacol Toxicol 2000; 7: 12.
34. th International Conference on Cytochrome P450, La Grande Motte, France, September 11-15, 2001; 70.
35. Venhorst J, Onderwater RCA, Meerman JHN, Commandeur JNM, Vermeulen NPE. Influence of N-substitution on 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. Drug Metab Dispos 2000; 28: 1524-1532.
36. Lewis DFV. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Pharmacol 2000; 60: 293-306.
37. Lewis DFV. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002; 32: 305-323.
38. Ferrari S, Leemann T, Dayer P. The role of lipophilicity in the inhibition of polymorphic cytochrome P4501ID6 oxidation by beta-blocking agents in vitro. Life Sci 1991; 48: 2259-2265.
39. Lewis DFV, Modi S, Dickins M. Structure-activity relationships for human cytochrome P450 substrates and inhibitors. Drug Metab Rev 2002; 34: 69-82.
40. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TYY. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47: 1151-1156.
41. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sunderg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
42. Mackman R, Tschirret-Guth RA, Smith G, Hayhurst GP, Ellis SW, Lennard MS, Tucker GT, Wolf CR, Ortiz de Montellano PR. Active-site topology of human CYP2D6 and its aspartate-301→glutamate, asparagine and glycine mutants. Arch Biochem Biophys 1996; 331: 134-140.
43. Lewis DFV. The CYP2 family: models, mutants and interactions. Xenobiotica 1998; 28: 617-661.
44. Tucker GT, Lennard MS, Ellis SW, Woods HF, Lin L, Hiratsuka A, Chu T, Cho AK. 'Ecstasy' is demethylenated by human cytochrome P450 2D6 (CYP2D6). Br J Clin Pharmacol 1993; 36: 144P.
45. Modi S, Gilham DE, Sutcliffe MJ, Lian L-Y, Primrose WU, Wolf CR, Roberts GCK. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P4502D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 1997; 36: 4461-4470.
46. Fischer V, Vickers AEM, Heitz F, Mahadevan S, Baldeck J-P, Minery P, Tynes R. The polymorphic cytochrome P450 2D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22: 269-274.
47. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 2089-2098.
48. Hansch C, Leo A, Hoekman D. Exploring QSAR: Hydrophobic, Electronic and Steric Constants. Washington, DC: American Chemical Society, 1995.
49. Dollery C. Therapeutic Drugs. Edinburgh: Churchill-Livingstone, 1999.
50. a values of medicinal compounds in pharmacy practice. Drug Intelligence Clin Pharm 1978; 12: 546-554.